These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

363 related items for PubMed ID: 20148650

  • 21. Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes.
    Moisseiev E, Waisbourd M, Ben-Artsi E, Levinger E, Barak A, Daniels T, Csaky K, Loewenstein A, Barequet IS.
    Graefes Arch Clin Exp Ophthalmol; 2014 Feb; 252(2):331-7. PubMed ID: 24170282
    [Abstract] [Full Text] [Related]

  • 22. Effect of bevacizumab on corneal neovascularization in experimental rabbit model.
    Ahmed A, Berati H, Nalan A, Aylin S.
    Clin Exp Ophthalmol; 2009 Sep; 37(7):730-6. PubMed ID: 19788671
    [Abstract] [Full Text] [Related]

  • 23. Effect of subconjunctival and intraocular bevacizumab injections on corneal neovascularization in a mouse model.
    Avisar I, Weinberger D, Kremer I.
    Curr Eye Res; 2010 Feb; 35(2):108-15. PubMed ID: 20136420
    [Abstract] [Full Text] [Related]

  • 24. Long-term tolerability and serum concentration of bevacizumab (avastin) when injected in newborn rabbit eyes.
    Wu WC, Lai CC, Chen KJ, Chen TL, Wang NK, Hwang YS, Yeung L, Li LM.
    Invest Ophthalmol Vis Sci; 2010 Jul; 51(7):3701-8. PubMed ID: 20181842
    [Abstract] [Full Text] [Related]

  • 25. Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis.
    Chen WL, Lin CT, Lin NT, Tu IH, Li JW, Chow LP, Liu KR, Hu FR.
    Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1659-65. PubMed ID: 18997093
    [Abstract] [Full Text] [Related]

  • 26. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin).
    Kim TI, Kim SW, Kim S, Kim T, Kim EK.
    Cornea; 2008 Apr; 27(3):349-52. PubMed ID: 18362666
    [Abstract] [Full Text] [Related]

  • 27. Concentration of cytokines in the aqueous humor of patients with naive, recurrent and regressed CNV associated with amd after bevacizumab treatment.
    Roh MI, Kim HS, Song JH, Lim JB, Koh HJ, Kwon OW.
    Retina; 2009 Apr; 29(4):523-9. PubMed ID: 19262441
    [Abstract] [Full Text] [Related]

  • 28. Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia.
    Chan WM, Lai TY, Chan KP, Li H, Liu DT, Lam DS, Pang CP.
    Retina; 2008 Oct; 28(9):1308-13. PubMed ID: 18728623
    [Abstract] [Full Text] [Related]

  • 29. Subretinal bevacizumab detection after intravitreous injection in rabbits.
    Dib E, Maia M, Longo-Maugeri IM, Martins MC, Mussalem JS, Squaiella CC, Penha FM, Magalhães O, Rodrigues EB, Farah ME.
    Invest Ophthalmol Vis Sci; 2008 Mar; 49(3):1097-100. PubMed ID: 18326736
    [Abstract] [Full Text] [Related]

  • 30. Preclinical pharmacokinetics of a recombinant humanized rabbit anti-VEGF monoclonal antibody in rabbits and monkeys.
    Yu DA, You M, Ji WW, Lu Y, Liu B, Yan SS.
    Toxicol Lett; 2018 Aug; 292():73-77. PubMed ID: 29709424
    [Abstract] [Full Text] [Related]

  • 31. Intravitreous bevacizumab injection: an experimental study in New Zealand white rabbits.
    Cortez RT, Ramirez G, Collet L, Thakuria P, Giuliari GP.
    Arch Ophthalmol; 2010 Jul; 128(7):884-7. PubMed ID: 20625050
    [Abstract] [Full Text] [Related]

  • 32. In vivo corneal endothelial safety of intracameral bevacizumab and effect in neovascular glaucoma combined with Ahmed valve implantation.
    Shin JP, Lee JW, Sohn BJ, Kim HK, Kim SY.
    J Glaucoma; 2009 Jul; 18(8):589-94. PubMed ID: 19826387
    [Abstract] [Full Text] [Related]

  • 33. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits.
    Gaudreault J, Fei D, Beyer JC, Ryan A, Rangell L, Shiu V, Damico LA.
    Retina; 2007 Jul; 27(9):1260-6. PubMed ID: 18046235
    [Abstract] [Full Text] [Related]

  • 34. Intraocular pharmacokinetics of intravitreal vascular endothelial growth factor-Trap in a rabbit model.
    Park SJ, Oh J, Kim YK, Park JH, Park JY, Hong HK, Park KH, Lee JE, Kim HM, Chung JY, Woo SJ.
    Eye (Lond); 2015 Apr; 29(4):561-8. PubMed ID: 25592118
    [Abstract] [Full Text] [Related]

  • 35. The effect of subconjunctival suramin on corneal neovascularization in rabbits.
    Lee HS, Chung SK.
    Cornea; 2010 Jan; 29(1):86-92. PubMed ID: 19907290
    [Abstract] [Full Text] [Related]

  • 36. Pharmacokinetics.
    Byeon SH, Kang SY.
    Ophthalmology; 2009 Jan; 116(1):168-9; author reply 169-70. PubMed ID: 19118710
    [No Abstract] [Full Text] [Related]

  • 37. Serum concentration of bevacizumab after intravitreal injection in experimental branch retinal vein occlusion.
    Chuang LH, Wu WC, Yeung L, Wang NK, Hwang YS, Chen KJ, Kuo JZ, Lai CC.
    Ophthalmic Res; 2011 Jan; 45(1):31-5. PubMed ID: 20714188
    [Abstract] [Full Text] [Related]

  • 38. [The pharmacokinetics of FK506 and its nanoparticles in aqueous humor of rabbits].
    Fei WL, Chen JQ, Zhong SL, Liu YM, Pang ZQ, Wang Z, Yuan J, Ye CT.
    Zhonghua Yan Ke Za Zhi; 2006 Apr; 42(4):305-8. PubMed ID: 16762205
    [Abstract] [Full Text] [Related]

  • 39. The effect of subconjunctival ranibizumab on corneal and anterior segment neovascularization: study on an animal model.
    Liarakos VS, Papaconstantinou D, Vergados I, Douvali M, Theodossiadis PG.
    Eur J Ophthalmol; 2014 Apr; 24(3):299-308. PubMed ID: 24242219
    [Abstract] [Full Text] [Related]

  • 40. Immunohistochemical localisation of intravitreally injected bevacizumab in the anterior chamber angle, iris and ciliary body of the primate eye.
    Peters S, Heiduschka P, Julien S, Bartz-Schmidt KU, Schraermeyer U.
    Br J Ophthalmol; 2008 Apr; 92(4):541-4. PubMed ID: 18211933
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.